Evidence map›Paper›PMID 35865358›Full record

ReviewCommunications medicine2022

Recommendations for achieving interoperable and shareable medical data in the USA.

Ana Szarfman, Jonathan G Levine, Joseph M Tonning, Frank Weichold, John C Bloom, Janice M Soreth, Mark Geanacopoulos, Lawrence Callahan, Matthew Spotnitz, Qin Ryan and 5 more

Abstract readReview
In one paragraph

Review in Communications medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Medical Digital Twin Technology for Interoperability: Challenges and Opportunities.Biomedical engineering and computational biology · 2026
    Review
  7. Enhancing antimicrobial resistance (AMR) surveillance data use in Uganda.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ana SzarfmanU.S. Food and Drug Administration, Silver Spring, MD 20993 USA.ORCID 0000-0001-6680-1423
Jonathan G LevineIndependent Researcher, Rockville, MD 20855 USA.ORCID 0000-0001-8078-2580
Joseph M TonningYour Health Concierge, Inc., Bethesda, MD 20815 USA.ORCID 0000-0003-2359-991X
Frank WeicholdU.S. Food and Drug Administration, Silver Spring, MD 20993 USA.ORCID 0000-0002-1232-178X
John C BloomCollege of Veterinary Medicine, Purdue University, West Lafayette, IN 47907 USA.ORCID 0000-0002-6427-3388
Janice M SorethIndependent Medical Consultant, Chevy Chase, 20815 MD USA.
Mark GeanacopoulosU.S. Food and Drug Administration, Silver Spring, MD 20993 USA.
Lawrence CallahanU.S. Food and Drug Administration, Silver Spring, MD 20993 USA.ORCID 0000-0002-5199-4979
Matthew SpotnitzColumbia University Irving Medical Center, New York, NY 10032 USA.ORCID 0000-0003-2869-0237
Qin RyanU.S. Food and Drug Administration, Silver Spring, MD 20993 USA.
Meg Pease-FyeU.S. Food and Drug Administration, Silver Spring, MD 20993 USA.ORCID 0000-0003-0360-1293
John S BrownsteinHarvard Medical School, Boston Children's Hospital, Boston, MA 02115 USA.ORCID 0000-0001-8568-5317
W Ed HammondDuke Center for Health Informatics, Duke Clinical & Translational Science Institute, Durham, NC 27705 USA.ORCID 0000-0003-2395-7676
Christian ReichColumbia University Department of Biomedical Informatics, New York, NY 10032 USA.ORCID 0000-0002-3641-055X
Russ B AltmanDepartments of Bioengineering, Genetics & Medicine, Stanford University, Stanford University School of Medicine, Stanford, CA 94305-4145 USA.ORCID 0000-0003-3859-2905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Easy access to large quantities of accurate health data is required to understand medical and scientific information in real-time; evaluate public health measures before, during, and after times of crisis; and prevent medical errors. Introducing a system in the USA that allows for efficient access to such health data and ensures auditability of data facts, while avoiding data silos, will require fundamental changes in current practices. Here, we recommend the implementation of standardized data collection and transmission systems, universal identifiers for individual patients and end users, a reference standard infrastructure to support calibration and integration of laboratory results from equivalent tests, and modernized working practices. Requiring comprehensive and binding standards, rather than incentivizing voluntary and often piecemeal efforts for data exchange, will allow us to achieve the analytical information environment that patients need.

Indexed as

Drug developmentPublic health

Identifiers

PMID35865358
PMCPMC9293957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.